Abstract Library

#4220 Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with 177Lutetium-DOTATATE

Introduction: 177Lutetium (Lu)-DOTATATE is an effective treatment for metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, radiation can cause transient inflammation/swelling of tumors which can result in toxicity. Treatment-related small bowel obstruction associated with mesenteric or peritoneal disease has been described.

Conference:

Presenting Author:

Authors: Pelle E, Al-Toubah T, El-Haddad G, Strosberg J,

Keywords: PRRT, Acute bowel ischemia, mesenteric metastasis,

#4112 Sexual dimorphism in small intestinal NETs: Any association with development of mesenteric metastases?

Introduction: Small-intestinal neuroendocrine tumors (SI-NET) are rising in incidence and complications such as mesenteric and hepatic metastases are associated with increased morbidity and mortality. It has recently been suggested that mesenteric metastases risk increases in women around menopause.

Conference:

Presenting Author: Castanho Martins M

Authors: Hassan D, Bally D, Castanho Martins M, Hodgetts H, Rombouts K,

Keywords: small intestine, mesenteric metastases, mesenteric fibrosis, sexual dimorphism, sex hormone,

#4055 Incidental endoscopic removal of a rectal neuroendocrine tumor: What to do?

Introduction: An increasing incidence of rectal neuroendocrine tumors (rNETs) has been reported as a consequence of the progressive spread of screening colonoscopy. Guidelines suggest endoscopic resection, preferably by endoscopic mucosal resection (EMR) or submucosal dissection, for rNETs

Conference:

Presenting Author: Terrin M

Authors: Rossi R, Terrin M, Carrara S, Maselli R, Hassan C,

Keywords: rectal neuroendocrine tumor, endoscopic resection, polypectomy,

#3887 Characteristics and management of high grade gastroenteropancreatic neuroendocrine neoplasms – A Belgian retrospective analysis from the DNET & NETwerk registry

Introduction: High grade gastroenteropancreatic neuroendocrine neoplasms (HG-GEPNEN) comprise neuroendocrine carcinoma (NEC) and well-differentiated neuroendocrine tumors (NETG3). These entities exhibit many differences in behaviour, prognosis and sensitivity to chemotherapy. Data about their optimal management are still scarce.

Conference:

Presenting Author:

Authors: Islam O, Sarti K, Verslype C, van Laethem J, Kalantari Hassan R,

Keywords: Neuroendocrine tumor, high-grade gastroenteropancreatic NEN (HG GEPNEN), neuroendocrine carcinoma, neuroendocrine tumor g3, retrospective data, clinical data, pathology,

#3730 Somatostatin receptor expression in lung neuroendocrine tumors – An analysis of Dotatate PET scans

Introduction: Somatostatin receptor (SSTR) expression in metastatic lung neuroendocrine (carcinoid) tumors has not been well-characterized using modern positron emission tomography (PET) imaging. Understanding the degree and uniformity of SSTR expression is important to establish the role of SSTR-targeted treatments, including peptide receptor radiotherapy (PRRT), in lung NETs.

Conference:

Presenting Author: Al-Toubah T

Authors: Al-Toubah T, Montilla-Soler J, El-Haddad G, Strosberg J,

Keywords: PET dotatate, cu64, ga68, lung NET, SSTR Positive,